| Multigene-expression tests for breast cancer |
HTA report (assessment) |
|
| Vitamin B12 tests |
Completed |
No change in criteria for reimbursement* (in German) Circular letter reimbursement analyses (in German)
|
| Medications against dementia in Alzheimer’s and Parkinson's disease |
Decision |
In progress |
| Hormone tests in suspected thyroid dysfunction |
Completed |
No change in criteria for reimbursement* Target agreement with specialist associations |
| Magnesium supplements |
HTA protocol |
|
| Use of betahistine or cinnarizine in Ménière’s disease, vertigo disorders or tinnitus |
Appraisal/ recommendation |
|
| Palbociclib (Ibrance®), ribociclib (Kisqali®) and abemaciclib (Verzenios®) as a treatment for advanced breast cancer |
Completed |
No change in criteria for reimbursement* |
| Use of the hormone Levothyroxine to treat a slightly underactive thyroid gland |
Completed |
Restriction on reimbursement (in German) |
| Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis |
Completed |
No change in criteria for reimbursement* |
| Sedative and sleep-promoting medicines for the treatment of chronic sleep disorders |
Decision |
In progress |
| Surgical widening of the subacromial space for the treatment of lower shoulder pain |
Decision |
In progress |
| Comparison of dosing schedules for drugs to treat bone metastases |
Decision |
In progress |
| Statins in the primary prevention of cardiovascular events and mortality in Switzerland |
Completed |
Restriction on reimbursement |
| The treatment of hypercholesterolaemia and mixed/combined hyperlipidaemia with ezetimibe-containing medicines |
Completed |
Restriction on reimbursement |
| Long-term physiotherapy after a stroke, in multiple sclerosis or Parkinson's disease |
Completed |
No change in criteria for reimbursement* |
| Vertebroplasty or kyphoplasty in patients with symptomatic osteoporotic vertebral compression fractures |
Completed |
Restriction on reimbursement (in German) |
| Denosumab (Prolia®) for the treatment of osteoporosis |
Decision |
In progress |
| Medical cannabis for treating various symptoms in Switzerland |
Completed |
No reimbursement (in German) |
| Corneal collagen crosslinking for the treatment of progressive keratoconus |
Completed |
Restriction on reimbursement (in German) |
| Chondroitin sulfate in osteoarthritis |
Decision |
Pending due to ongoing appeal |
| Blood thinner treatment after stent surgery |
Completed |
No change in criteria for reimbursement* |
| Vitamin D Testing |
Completed |
Restriction on reimbursement (in German) |
| Oral anticoagulants for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation |
Completed |
No change in criteria for reimbursement* |
| Point-of-care diagnostic tests |
Due to the intensive work on transAL-2, the HTA "Point-of-care diagnostic tests" is currently on hold. It will be resumed as soon as resources become available in the section responsible for transAL-2 (review of analysis list tariffs) given sufficient progress on that project. |
|
| Treatment of osteoarthritis of the knee and the hip via glucocorticoid injection |
Decision |
In progress |
| Prevention of chronic and episodic migraine with CGRP antagonists |
Completed |
Temporary admission with restriction on reimbursement (Ajovy, Aimovig, Emgality, Vypeti; in German) |
| Comparison of surgical improvement of vascular blood flow with drug therapy in subjects with chronic cardiovascular disease |
Decision |
In progress |
| Antidepressants for depression |
Completed |
No change in criteria for reimbursement* |
| Reduced duration of trastuzumab treatment in HER2-positive early breast cancer |
Decision |
In progress |
| Olmesartan mono- and combination therapies in patients with essential hypertension |
Completed |
No change in criteria for reimbursement* |
| Treatment of non-erosive gastroesophageal reflux disease patients with proton pump inhibitors |
Decision |
In progress |
| Iron therapy for iron deficiency without anaemia |
Decision |
Pending due to ongoing appeal |
| Glinides and glitazones in people with diabetes |
Completed |
Restriction on reimbursement |
| Blood glucose self-monitoring in people with insulin-untreated type 2 diabetes mellitus |
Completed |
Restriction on reimbursement (in German) |
| Folate tests for suspected folate deficiency |
Appraisal/ recommendation |
|
| Knee arthroscopy for the treatment of degenerative changes |
Decision |
In progress |
| Removal of osteosynthesis materials (e.g. screws, plates, nails and wires) used to treat bone fractures |
Completed |
No change in criteria for reimbursement* |
| Spinal implants in patients with therapy-resistant pain and/or neurological symptoms |
Completed |
Restriction on reimbursement (in German) |
| Tumor treating fields (TTFields) for patients with glioblastoma |
Completed |
Change in criteria for reimbursement (in German) |
| Immunotherapy with CAR-T cells to treat blood cancer and lymph node cancer |
Appraisal/ recommendation |
|
| Thermoablation for benign thyroid nodules |
Pre-Scoping |
|
| Injection therapies with corticosteroids for chronic tendinopathy or enthesopathy |
Pre-Scoping |
|
| Superficial/deep heat in physiotherapy for musculoskeletal conditions |
Pre-Scoping |
|
| Bronchial thermoplasty for severe asthma |
Pre-Scoping |
|
| Valerian extracts for sleep disorders, anxiety or restlessness |
Pre-Scoping |
|
| Benzodiazepines for anxiety disorders |
Pre-Scoping |
|
| Trikafta® for the treatment of patients with cystic fibrosis |
Completed |
Temporary admission with restriction on reimbursement (in German) |
| Ginkgo biloba in patients with decreasing mental performance, peripheral arterial occlusive disease, vertigo or tinnitus |
Pre-Scoping |
|
| Use of the medications oseltamivir and baloxavir marboxil to prevent or treat flu |
Appraisal/ recommendation |
|
| Inpatient anthroposophic complex treatment |
HTA protocol |
|
